Biophan Technologies, Inc., a developer of next-generation medical technology, in conjunction with MYOTECH, LLC, recently presented results of animal studies that indicate the potential of the MYO-VAD, a cardiac support system to significantly improve the treatment of heart failure. The MYO-VAD restores cardiac output on an arrested or weak heart. The device can be implanted in approximately three minutes.
The U.S. Food and Drug Administration (FDA) today approved Celebrex (celecoxib) for a new use ? the relief of the signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) in patients two years of age and older. Today’s approval follows the November 29 meeting of FDA’s Arthritis Advisory Committee, in which the committee voted 15 to 1 in favor of approval of this product.
Scientific, technological and medical advances made in the past two decades are leading to more definitive diagnoses, earlier and more effective treatment options and better outcomes for patients suffering from a condition called acromegaly, according to an article published in today’s issue of the New England Journal of Medicine and authored by a specialist in endocrinology at Cedars-Sinai Medical Center.
Researchers say Americans with high blood pressure are doing a better job of controlling their high blood pressure, hypertension. A new study shows that a third of U.S. adults with high blood pressure had good blood pressure control in 2003-2004. That’s up 8 percent from 1999-2000, the study shows. The study is published in the American Heart Association journal Hypertension.
Physicians who once treated mainly elderly patients for health problems such as diabetes, heart disease and stroke are seeing increasingly younger patients who have the same ailments.
The 2006 American College of Neuropsychopharmacology annual meeting will feature hundreds of new studies on brain and behavior from the world’s leading scientists. Presentations include innovative research on potential new treatments for Alzheimer’s disease, autism, nicotine addiction and treatment resistant depression.
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
The turbidity of red wine during its ageing in oak casks has an influence on the accumulation of volatile compounds and, thereby, on the wine’s aroma, but not on the accumulation of biogenic amines. This is the conclusion of Nerea Jim?nez Moreno in her PhD thesis defended at the Public University of Navarre.
King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the launch of a new program that will provide support for patients with diabetes who are receiving treatment with Glumetza (metformin hydrochloride extended-release tablets), a new once-daily extended-release metformin formulation that features AcuForm drug-delivery technology.
Compounds known to play an important role in how insects develop from larvae to adults have been shown in a mouse model for congestive heart failure to be effective in preventing and reducing cardiac cell overgrowth and irregular heart rhythms, according to UC Davis research published in the early online edition of the Proceedings of the National Academy of Sciences.